Head to Head Survey: Nephros (NASDAQ:NEPH) and InterCure (NASDAQ:INCR)

Nephros (NASDAQ:NEPH) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings & Valuation

This table compares Nephros and InterCure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79 million	2.10	$1.19 million	$0.07	51.86
InterCure	$78.47 million	0.59	-$10.37 million	$0.03	28.33

Nephros has higher earnings, but lower revenue than InterCure. InterCure is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Nephros and InterCure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0	1	1	0	2.50
InterCure	1	0	0	0	1.00

Nephros currently has a consensus price target of $6.00, suggesting a potential upside of 65.29%. Given Nephros’ stronger consensus rating and higher possible upside, equities analysts plainly believe Nephros is more favorable than InterCure.

Profitability

This table compares Nephros and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
InterCure	N/A	N/A	N/A

Insider and Institutional Ownership

41.1% of Nephros shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Nephros has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Summary

Nephros beats InterCure on 13 of the 14 factors compared between the two stocks.

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.